Helicobacter pylori eradication-treatment regimen + metformin
Helicobacter pylori eradication-treatment regimen + metformin has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Nov 15, 2026: “Effects of a Helicobacter pylori -directed treatment regimen combined with metformin on glycemic control and metabolic and inflammatory status in type 2 diabetes mellitus”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1 papers on helicobacter pylori eradication-treatment regimen + metformin
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Assignment to the Helicobacter pylori eradication-treatment regimen combined with metformin was associated with greater short-term glycated hemoglobin improvement than assignment to either regimen alone.”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave helicobacter pylori eradication-treatment regimen + metformin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases glycated hemoglobinGreater reduction of 1.76 percentage points versus eradication-treatment regimen alone (95% CI 1.43–2.09) and 1.77 percentage points versus metformin alone (95% CI 1.41–2.13) no change: Has no effect on complication incidence | Randomized trial6 months | 120 peopleadultType 2 diabetes mellitus and Helicobacter pylori infection; comparison with either regimen alone using archived summary data | The Journal of international medical research, Nov 15, 2026 |
What did studies of helicobacter pylori eradication-treatment regimen + metformin find?
2Studies of helicobacter pylori eradication-treatment regimen + metformin measured 2 outcomes: complication incidence and glycated hemoglobin.
Complication incidence
no changein humans1
1 study
Complication incidence
no changein humans1
Helicobacter pylori eradication-treatment regimen + metformin showed no clear effect on complication incidence in humans Across the eradication-treatment regimen, metformin, and combined-treatment groups.
“Complication incidence did not differ significantly among groups (P = 0.114).”
Human trialAcross the eradication-treatment regimen, metformin, and combined-treatment groups6 monthsn = 120
The Journal of international medical research
Glycated hemoglobin
downin humans1
1 study
Glycated hemoglobin
downin humans1
Helicobacter pylori eradication-treatment regimen + metformin decreases glycated hemoglobin in humans (Greater reduction of 1.76 percentage points versus eradication-treatment regimen alone (95% CI 1.43–2.09) and 1.77 percentage points versus metformin alone (95% CI 1.41–2.13)).
“Assignment to the Helicobacter pylori eradication-treatment regimen combined with metformin was associated with greater short-term glycated hemoglobin improvement than assignment to either regimen alone.”
Human trialType 2 diabetes mellitus and Helicobacter pylori infection; comparison with either regimen alone using archived summary data6 monthsn = 120
The Journal of international medical research